Budget Impact Analysis of Mepolizumab for Eligible Patients in the Setting of a Severe Asthma Clinic Within Dubai Health Authority (DHA)

References

• Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.00202013
   PubMed Web of Science ®Google Scholar
• Louis R. Severe asthma: how can we differentiate phenotypes? Swiss Med Wkly. 2009;139(19–20):247–277.
   Web of Science ®Google Scholar
• Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18(5):716. doi:10.1038/nm.2678
   PubMed Web of Science ®Google Scholar
• Kuruvilla ME, Lee FE, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol. 2019;56(2):219–233. doi:10.1007/s12016-018-8712-1
   PubMed Web of Science ®Google Scholar
• Pavlidis STakahashi K, Kwong FN, et al. “T2-high” in severe asthma related to blood eosinophilexhaled nitric oxide and serum periostin. Eur Respir J. 2019;3553(1).
   Google Scholar
• Bakakos A, Loukides S, Bakakos P. Severe eosinophilic asthma. J Clin Med. 2019;8(9):1375. doi:10.3390/jcm8091375
   PubMed Web of Science ®Google Scholar
• Pelaia C, Paoletti G, Puggioni F, et al. Interleukin-5 in the pathophysiology of severe asthma. Front Physiol. 2019;10:1514. doi:10.3389/fphys.2019.01514
   PubMed Web of Science ®Google Scholar
• Latham and Watkins. Healthcare regulation in the UAE; 2011 [ cited September 15, 2020]. Available from: https://www.lw.com/upload/pubContent/_pdf/pub3951_1.pdf. Accessed April 6, 2022.
   Google Scholar
• Khadadah M, Mahboub B, Al-Busaidi NH, et al. Asthma insights and reality in the gulf and the Near East. Int J Tuberc Lung Dis. 2009;13(8):1015–1022.
   PubMed Web of Science ®Google Scholar
• Government of Dubai. About Rashid Hospital; 2020 [ cited October 6, 2020]. Available from: https://www.dha.gov.ae/en/RashidHospital/pages/aboutrashidhospital.aspx. Accessed April 6, 2022.
   Google Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II Task Force. Value Health. 2014;17(1):5–14. doi:10.1016/j.jval.2013.08.2291
   PubMed Web of Science ®Google Scholar
• Nucala: EPAR-product information; 2019.
   Google Scholar
• Xolair-EPAR: product Information; 2020.
   Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa1403290
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–316. doi:10.1111/j.1398-9995.2004.00772.x
   PubMed Web of Science ®Google Scholar
• Bousquet J, Siergiejko Z, Świebocka E, et al. Persistency of response to omalizumab therapy in severe allergic (IgE‐mediated) asthma. Allergy. 2011;66(5):671–678. doi:10.1111/j.1398-9995.2010.02522.x
   PubMed Web of Science ®Google Scholar
• Chang H-L, Hsu J-F, Tsai Y-M, Lin S-Y, Kuo H-F, Yang C-J. Drop-out rate among patients treated with omalizumab for severe asthma: literature review and real life experience. BMC Pulm Med. 2016;16:1–9. doi:10.1186/s12890-015-0163-3
   PubMed Web of Science ®Google Scholar
• WHO collaborating center for drug statistics methodology Norwegian Institute of Public Health; 2021.
   Google Scholar
• DHA. eClaimLink; 2012 [ cited September 21, 2019]; Available from: https://www.eclaimlink.ae/NoneRegisteredCodingSets.aspx. .Accessed April 6, 2022.
   Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197. doi:10.1056/NEJMoa1403291
   PubMed Web of Science ®Google Scholar
• Carpagnano GE, Pelaia C, D’Amato M, et al. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy. Ther Adv Respir Dis. 2020;14:175346662092923. doi:10.1177/1753466620929231
   Web of Science ®Google Scholar
• Albers FC, Necdet HM, Gunsoy B, et al. Biologic treatment eligibility for real-world patients with severe asthma: the IDEAL study. J Asthma. 2018;55:152–160. doi:10.1080/02770903.2017.1322611
   PubMed Web of Science ®Google Scholar
• NCPE. Cost-Effectiveness of Omalizumab (Xolair^®) for the Treatment of Severe Allergic Asthma. Ireland: National Centre for Pharmacoeconomics; 2015.
   Google Scholar
• World Health Organization. Omalizumab Defined Daily Dose (DDD); 2019 [ cited September 24, 2020]. Available from: https://www.whocc.no/atc_ddd_index/?code=R03DX05&showdescription=no. Accessed April 6, 2022.
   Google Scholar
• Benralizumab for treating severe eosinophilic asthma; 2018 [ cited September 24, 2020]. Available from: https://www.nice.org.uk/guidance/ta565/documents/final-appraisal-determination-document. Accessed April 6, 2022.
   Google Scholar
• Assessment report: fasenra; 2018 [ cited September 24, 2020]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/fasenra-epar-public-assessment-report_en.pdf. Accessed April 6, 2022.
   Google Scholar
• Biologic therapies for treatment of asthma associated with type 2 inflammation: effectiveness, value, and value-based price benchmarks; 2018. [ cited September 24, 2020]; Available from: https://icer-review.org/wp-content/uploads/2018/04/Asthma-Revised-Report-FOR-PUBLICATION-11.13.2018.pdf. Accessed April 6, 2022.
   Google Scholar
• Busse W, Chupp G, Nagase H, et al. Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison. J Allergy Clin Immunol. 2019;143(1):190–200. doi:10.1016/j.jaci.2018.08.031
   PubMed Web of Science ®Google Scholar
• Carpagnano GE, Resta E, Povero M, et al. Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma. Sci rep2021;11(5453).
   Google Scholar
• Lefebvre P, Duh MS, Lafeuille MH, et al. Acute and chronic systemic corticosteroid–related complications in patients with severe asthma. J Allergy Clin Immunol. 2015;136(6):1488–1495. doi:10.1016/j.jaci.2015.07.046
   PubMed Web of Science ®Google Scholar
• Mahboub B. Budget impact analysis of mepolizumab for eligible patients in the setting of a severe asthma clinic within Dubai health authority (DHA). 25th Dubai International Pharmaceutical & Technology Conference & Exhibition (DUPHAT); 2019; Dubai: Dubai International Convention Centre (DICC).
   Google Scholar
• Genentech USA Inc. and Novartis Pharmaceuticals Corporation. XOLAIR dosing for allergic asthma; 2020 [ cited October 5, 2020]. Available from: https://www.xolairhcp.com/starting-treatment/dosing.html. Accessed April 6, 2022.
   Google Scholar
• Lowe PJ, Janice Canvin PG. Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE. Regulatory Toxicol Pharmacol. 2015;71(1);71
   Web of Science ®Google Scholar
• medications. M.o.H.a.P.M.p.l.o.r; 2021.
   Google Scholar